IP Library Granted Patent US 9,005,190
Granted Patent B2
US 9,005,190 · App. 14/075,908 · Granted Apr 14, 2015

Treatment of non-alcoholic fatty liver disease

Inventors: Bobak Robert Azamian (Newport Coast, CA); Jonathan Allen Coe (Menlo Park, CA); Scott Bradley Vafai (Boston, MA)
Assignee: Metavention, Inc.
A61B18/1815A61B18/18A61B18/1492A61N7/022A61B18/24A61B2018/00023A61B2018/0022A61B2018/00404A61B2018/00434A61B2018/00529A61B2018/00577A61B2018/00791A61B2018/00839A61B2018/0212A61B2018/048A61B17/320068A61N5/00A61B17/00A61B17/32A61B18/02A61B18/04A61B18/06A61N7/00A61B17/00234A61B2017/00318A61B2018/1861
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,190
App. No.
14/075,908
Granted
Apr 14, 2015
Kind
B2
Abstract

According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.

Claims (34)

1. A method of treating non-alcoholic fatty liver disease, comprising:

positioning a distal portion of an energy delivery device within a common hepatic artery of a subject;

at least partially blocking one or more sympathetic nerves that innervate a liver using the energy delivery device by intravascularly delivering energy through a wall of the common hepatic artery at a target location sufficient to treat non-alcoholic fatty liver disease; and

removing the energy delivery device from the subject,

wherein the energy delivery device is configured to contact the wall of a portion of the common hepatic artery at the target location while the energy is being delivered.

2. The method of claim 1 , wherein the energy delivery device comprises one or more electrodes, and wherein the energy delivered by the energy delivery device comprises radiofrequency (RF) energy delivered by the one or more electrodes.

3. The method of claim 1 , wherein the energy delivery device comprises one or more ultrasound transducers.

4. The method of claim 1 , further comprising at least partially occluding the portion of the common hepatic artery.

5. The method of claim 4 , wherein at least partially occluding the portion of the hepatic artery comprises fully occluding the portion of the common hepatic artery.

6. The method of claim 1 , wherein the energy delivery device comprises a balloon catheter configured to at least partially occlude the portion of the common hepatic artery.

7. The method of claim 6 , wherein the balloon catheter comprises one or more electrodes configured to contact the wall of the common hepatic artery upon expansion of at least one balloon of the balloon catheter.

8. The method of claim 1 , wherein the energy delivery device comprises a catheter with a flexible distal end configured to navigate arterial anatomy having a bend radius of 5 mm.

9. The method of claim 2 ,

wherein the RF energy is delivered at a frequency in the range of 50 kHz to 5 MHz; and

wherein the RF energy is delivered to heat the one or more sympathetic nerves to a temperature of up to 90 degrees Celsius and sufficient to cause ablation of the one or more sympathetic nerves.

10. The method of claim 3 , wherein the energy is delivered at a frequency in the range of 20 kHz to 20 MHz.

11. The method of claim 1 , further comprising providing cooling to a portion of a tissue that is not being targeted by the energy.

12. A method of treating non-alcoholic fatty liver disease, comprising:

positioning a distal end of a neuromodulation device within a hepatic artery segment of a subject;

modulating one or more nerves that innervate a liver using the neuromodulation device sufficient to treat non-alcoholic fatty liver disease; and

removing the neuromodulation device from the subject,

wherein at least a portion of the distal end of the neuromodulation device is configured to contact a wall of the hepatic artery segment at a target location while the one or more nerves are being modulated.

13. The method of claim 12 , wherein the neuromodulation device is delivered intravascularly through a femoral or radial artery to the target location within the hepatic artery segment.

14. The method of claim 12 , wherein the neuromodulation device comprises an radiofrequency (RF) energy delivery catheter comprising one or more electrodes at a distal section of the RF energy delivery catheter configured to contact the wall of the hepatic artery segment while the one or more nerves are being modulated.

15. The method of claim 12 , wherein modulating the one or more nerves comprises denervating one or more sympathetic nerves of a hepatic plexus.

16. The method of claim 12 , further comprising at least partially occluding the hepatic artery segment.

17. The method of claim 12 , wherein a contact pressure between 0.1 g/mm 2 and 100 g/mm 2 is exerted on the wall.

18. A method of treating non-alcoholic fatty liver disease, comprising:

providing an energy delivery catheter configured for:

accessing a portion of vasculature in the vicinity of a hepatic plexus of a subject; and

delivering energy through a wall of the vasculature sufficient to modulate one or more nerves of the hepatic plexus,

wherein modulation of the one or more nerves effects treatment of non-alcoholic fatty liver disease.

19. The method of claim 18 , wherein the energy comprises radiofrequency (RF) energy delivered to the one or more nerves at a frequency in the range of 50 kHz to 5 MHz, and wherein the RF energy is delivered to heat the one or more nerves to a temperature of up to 90 degrees Celsius and sufficient to cause ablation of the one or more nerves.

20. The method of claim 18 , wherein at least a portion of a distal end of the energy delivery catheter is configured to contact the wall of a hepatic artery segment within the vasculature at a target location while the one or more nerves are being modulated.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2023
From: METAVENTION, INC.
To: MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY
Reel/Frame 064987/0161 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2023
From: CUSTOMERS BANK (SUCCESSOR IN INTEREST TO SIGNATURE BANK)
To: METAVENTION, INC.
Reel/Frame 064670/0039 →
SECURITY INTEREST Recorded Jan 11, 2023
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 062349/0859 →
SECURITY INTEREST Recorded Oct 31, 2022
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 061602/0249 →
SECURITY INTEREST Recorded Jun 29, 2022
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 060358/0417 →
SECURITY INTEREST Recorded Dec 20, 2021
From: METAVENTION, INC.
To: SIGNATURE BANK
Reel/Frame 058433/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: AZAMIAN, BOBAK ROBERT; COE, JONATHAN ALLEN; VAFAI, SCOTT BRADLEY
To: METAVENTION, INC.
Reel/Frame 031578/0683 →
Continuity (4)
Continuation 13789509 · Mar 7, 2013
Continuation PCTUS2012068630 · Dec 7, 2012
Provisional Application 61568843 · Dec 9, 2011
Related Publication 20140066919A1 · Mar 6, 2014